$KNTK

ISQ Global Fund II GP LLC (Wahba Sadek, Bhandari Gautam) sold $14.3M of KNTK (indirect holdings)

ISQ Global Fund II GP LLC sold 265,572 indirectly-held shares of Kinetik Holdings Inc. (KNTK) at an average of $54.03 ($53.59–$54.72, $14.35M total) across 4 trades over 2026-09-17 to 2026-09-21. Filed jointly with I Squared Capital, LLC (10% owner), ISQ Holdings, LLC (10% owner), Wahba Sadek (10% owner) and Bhandari Gautam (10% owner).

Original reporting
SEC EDGAR · ISQ Global Fund II GP LLC, I Squared Capital, LLC, ISQ Holdings, LLC, Wahba Sadek, Bhandari Gautam
Published Sep 21, 2026, 11:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 12:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KNTK
Bearish
medium confidence
Mentioned
$KNTK
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KNTKBearishLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be interpreted by the market as reduced confidence.

02

Market read

Primary insider sell; modest trading relevance for short‑term investors.

03

What to watch

Potential upcoming catalyst such as a clinical trial update may offset the sell pressure.

Relevance 7/10Novelty 6/10Timing: post‑market 2026‑09‑21

Background

SEC Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$KNTKBearishMedium confidence
Context

Form 4 disclosed a $14.3M open‑market sale by a 10% owner, reducing holdings to 448,273 shares.

Expected impact

Possible modest downside of 2‑4% over the next few days.

Evidence & confidence

Insider sold ~265k shares at $54 average, a sizable stake for a micro‑cap; such sales often precede price weakness.

Market effects

Minimal; the sale is company‑specific and does not affect the broader biotech sector.

None; the transaction is confined to US investors.

Low; no cross‑border or macro implications.

Counterpoint

The sale could be a routine liquidity event rather than a bearish signal.

Key entities

  • Kinetik Holdings Inc.

    US‑listed biotech firm (ticker KNTK).

  • ISQ Global Fund II GP LLC

    10% owner reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KNTKMedAI 8/10

Why is Kinetik Holdings stock surging today?

Kinetik Holdings' stock rose 5.2% in after-hours trading after Bloomberg reported the company is exploring strategic alternatives, including a potential sale. The company posted record Q2 2026 results with revenue up 36% YoY and net income more than doubled. Kinetik's management had raised its full-year 2026 guidance. U.S. equities broadly sold off during regular trading hours, with the S&P 500, Dow Jones, and Nasdaq all declining.

Med

Kinetik stock jumps 5% on potential sale exploration report

Kinetik Holdings Inc. (KNT) shares rose 5% in after-hours trading after reports it is exploring strategic options, including a potential sale. The company, backed by Blackstone Inc. (BX), has a market value of $8.9B. No final decision has been made. Kinetik closed regular trading at $54.55, down 0.8% but up 30% over the past year.

$KNTKMed

Kinetik Q2 Earnings Call Highlights

Kinetik (NYSE:KNTK) Q2 earnings call said Waha pricing normalization and faster curtailment return, higher WTI and liquids assumptions, and system operating improvements supported a revised outlook. It raised 2026 capex to about $560M, expects Q3 Adjusted EBITDA $260M-$270M and Q4 $270M-$280M, and lifted 2026 volume growth to mid- to high-single digits.